A cog in cognition: How the α7 nicotinic acetylcholine receptor is geared towards improving cognitive deficits

Pharmacology and Therapeutics

Volumn 122, Issue 3, 2009, Pages 302-311

  Leiser, Steven C ^a   Bowlby, Mark R ^a   Comery, Thomas A ^a   Dunlop, John ^a  

^a PFIZER INC   (United States)

Author keywords

Alpha7 nAChR; Cognition; EEG; Evoked potentials; Sensory gating

Indexed keywords

BIOLOGICAL MARKER; BUNGAROTOXIN RECEPTOR; NICOTINIC AGENT; NICOTINIC RECEPTOR;

ATTENTION; BRAIN CORTEX; COGNITION; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DRUG TARGETING; ELECTROENCEPHALOGRAPHY; EVENT RELATED POTENTIAL; EVOKED AUDITORY RESPONSE; GENETIC ANALYSIS; HIPPOCAMPUS; HUMAN; MENTAL DISEASE; NONHUMAN; PREPULSE INHIBITION; PRIORITY JOURNAL; RECOGNITION; REVIEW; SCHIZOPHRENIA; SENSORIMOTOR FUNCTION; SENSORY NERVE; STARTLE REFLEX; WORKING MEMORY;

ANIMALS; COGNITION; COGNITION DISORDERS; HUMANS; PROTEIN BINDING; RECEPTORS, NICOTINIC;

EID: 67349209574     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2009.03.009     Document Type: Review

References (178)

1. Acri J.B., Morse D.E., Popke E.J., and Grunberg N.E. Nicotine increases sensory gating measured as inhibition of the acoustic startle reflex in rats. Psychopharmacology (Berl) 114 2 (1994) 369-374
2. Adams C.E., Stitzel J.A., Collins A.C., and Freedman R. Α7-nicotinic receptor expression and the anatomical organization of hippocampal interneurons. Brain Res 922 (2001) 180-190
3. Adler L.E., Pachtman E., Franks R.D., Pecevich M., Waldo M.C., and Freedman R. Neurophysiological evidence for a defect in neuronal mechanisms involved in sensory gating in schizophrenia. Biol Psychiatry 17 6 (1982) 639-654
4. Adler L.E., Olincy A., Waldo M., Harris J.G., Griffith J., et al. Schizophrenia, sensory gating, and nicotinic receptors. Schizophr Bull 24 (1998) 189-202
5. Alkondon M., Pereira E.F., and Albuquerque E.X. Alpha-bungarotoxin- and methyllycaconitine-sensitive nicotinic receptors mediate fast synaptic transmission in interneurons of rat hippocampal slices. Brain Res 810 1-2 (1998) 257-263
6. Amann L.C., Phillips J.M., Halene T.B., and Siegel S.J. Male and female mice differ for baseline and nicotine-induced event related potentials. Behav Neurosci 122 5 (2008) 982-990
7. Arendash G.W., Sengstock G.J., Sanberg P.R., and Kem W.R. Improved learning and memory in aged rats with chronic administration of the nicotinic receptor agonist GTS-21. Brain Res, 674 2 (1995) 252-259
8. Aşçioglu M., Dolu N., Gölgeli A., Süer C., and Ozesmi C. Effects of cigarette smoking on cognitive processing. Int J Neurosci 114 3 (2004) 381-390
9. Baker N., Adler L.E., Franks R.D., Waldo M., Berry S., et al. Neurophysiological assessment of sensory gating in psychiatric inpatients: comparison between schizophrenia and other diagnoses. Biol Psychiatry 22 5 (1987) 603-617
10. Bancroft A., and Levin E.D. Ventral hippocampal alpha4beta2 nicotinic receptors and chronic nicotine effects on memory. Neuropharmacology 39 13 (2000) 2770-2778
11. Boess F.G., De Vry J., Erb C., Flessner T., Hendrix M., et al. The novel alpha7 nicotinic acetylcholine receptor agonist N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-[2-(methoxy)phenyl]-1-benzofuran- 2-carboxamide improves working and recognition memory in rodents. J Pharmacol Exp Ther 321 2 (2007) 716-725
12. Boutros N.N., Belger A., Campbell D., D'Souza C., and Krystal J. Comparison of four components of sensory gating in schizophrenia and normal subjects: a preliminary report. Psychiatry Res 88 (1999) 119-130
13. Boutros N.N., Bonnet K.A., Millana R., and Liu J. A parametric study of the N40 auditory evoked response in rats. Biol Psychiatry 42 (1997) 1051-1059
14. Boutros N., Nasrallah H., Leighty R., Torello M., Tueting P., and Olson S. Auditory evoked potentials, clinical vs. research applications. Psychiatry Res 69 (1997) 183-195
15. Boutros N.N., Korzyukov O., Jansen B., Feingold A., and Bell M. Sensory gating deficits during the mid-latency phase of information processing in medicated schizophrenia patients. Psychiatry Res 126 (2004) 203-215
16. Boutros N.N., Mears R., Pflieger M.E., Moxon K.A., Ludowig E., and Rosburg T. Sensory gating in the human hippocampal and rhinal regions: regional differences. Hippocampus 18 3 (2008) 310-316
17. Braff D.L., Light G.A., and Swerdlow N.R. Prepulse inhibition and P50 suppression are both deficient but not correlated in schizophrenia patients. Biol Psychiatry 61 10 (2007) 1204-1207
18. Bramon E., Rabe-Hesketh S., Sham P., Murray R.M., and Frangou S. Meta-analysis of the P300 and P50 waveforms in schizophrenia. Schizophr Research 70 2-3 (2004) 315-329
19. Briggs C.A., Anderson D.J., Brioni J.D., Buccafusco J.J., Buckley M.J., et al. Functional characterization of the novel neuronal nicotinic acetylcholine receptor ligand GTS-21 in vitro and in vivo. Pharmacol Biochem Behav 57 1-2 (1997) 231-241
20. Buccafusco J.J., and Jackson W.J. Beneficial effects of nicotine administered prior to a delayed matching-to-sample task in young and aged monkeys. Neurobiol Aging 12 3 (1991) 233-238
21. Buccafusco J.J., Terry Jr. A.V., Decker M.W., and Gopalakrishnan M. Profile of nicotinic acetylcholine receptor agonists ABT-594 and A-582941, with differential subtype selectivity, on delayed matching accuracy by young monkeys. Biochem Pharmacol 74 8 (2007) 1202-1211
22. Butler P.D., Schechter I., Zemon V., Schwartz S.G., Greenstein V.C., et al. Dysfunction of early-stage visual processing in schizophrenia. Am J Psychiatry 158 7 (2001) 1126-1133
23. Buzsáki G. Theta oscillations in the hippocampus. Neuron 33 3 (2002) 325-340
24. Caine S.B., Geyer M.A., and Swerdlow N.R. Hippocampal modulation of acoustic startle and prepulse inhibition in the rat. Pharmacol Biochem Behav 43 4 (1992) 1201-1208
25. Chan W.K., Wong P.T., and Sheu F.S. Frontal cortical alpha7 and alpha4beta2 nicotinic acetylcholine receptors in working and reference memory. Neuropharmacology 52 8 (2007) 1641-1649
26. Cilia J., Cluderay J.E., Robbins M.J., Reavill C., Southam E., et al. Reversal of isolation-rearing-induced PPI deficits by an alpha7 nicotinic receptor agonist. Psychopharmacology (Berl) 182 2 (2005) 214-219
27. Clementz B.A., and Blumenfeld L.D. Multichannel electroencephalographic assessment of auditory evoked response suppression in schizophrenia. Exp Brain Res 139 (2001) 377-390
28. Clementz B.A., Blumenfeld L.D., and Cobb S. The gamma band response may account for poor P50 suppression in schizophrenia. Neuroreport 8 18 (1997) 3889-3893
29. Clementz B.A., Geyer M.A., and Braff D.L. Multiple site evaluation of P50 suppression among schizophrenia and normal comparison subjects. Schizophr Research 30 1 (1998) 71-80
30. Cotillon-Williams N., and Edeline J.M. Evoked oscillations in the thalamo-cortical auditory system are present in anesthetized but not in unanesthetized rats. J Neurophysiol 89 4 (2003) 1968-1984
31. Connolly P.M., Maxwell C.R., Kanes S.J., Abel T., Liang Y., et al. Inhibition of auditory evoked potentials and prepulse inhibition of startle in DBA/2J and DBA/2Hsd inbred mouse substrains. Brain Res 992 1 (2003) 85-95
32. Connolly P.M., Maxwell C., Liang Y., Kahn J.B., Kanes S.J., et al. The effects of ketamine vary among inbred mouse strains and mimic schizophrenia for the P80, but not P20 or N40 auditory ERP components. Neurochem Research 29 6 (2004) 1179-1188
33. Court J., Martin-Ruiz C., Piggott M., Spurden D., Griffiths M., and Perry E. Nicotinic receptor abnormalities in Alzheimer's disease. Biol Psychiatry 49 (2001) 175-184
34. Dani J.A., and Bertrand D. Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. Annu Rev Pharmacol Toxicol 47 (2007) 699-729
35. Dimpfel W. Preclinical data base of pharmaco-specific rat EEG fingerprints (tele-stereo-EEG). Eur J Med Research 8 5 (2003) 199-207
36. Dimpfel W. Pharmacological modulation of cholinergic brain activity and its reflection in special EEG frequency ranges from various brain areas in the freely moving rat (Tele-Stereo-EEG). Eur Neuropsychopharmacol 15 6 (2005) 673-682
37. Dunbar G., Boeijinga P.H., Demazières A., Cisterni C., Kuchibhatla R., et al. Effects of TC-1734 (AZD3480), a selective neuronal nicotinic receptor agonist, on cognitive performance and the EEG of young healthy male volunteers. Psychopharmacology (Berl) 191 4 (2007) 919-929
38. Dunlop J., Lock T., Jow B., Sitzia F., Grauer S., et al. Old and new pharmacology, positive allosteric modulation of the alpha7 nicotinic acetylcholine receptor by the 5-hydroxytryptamine(2B/C) receptor antagonist SB-206553 (3,5-dihydro-5-methyl-N-3-pyridinylbenzo[1,2-b,4,5-b']di pyrrole-1(2H)-carboxamide). J Pharmacol Exp Ther 328 3 (2009) 766-776
39. Ehrlichman R.S., Gandal M.J., Maxwell C.R., Lazarewicz M.T., Finkel L.H., et al. N-methyl-d-aspartic acid receptor antagonist-induced frequency oscillations in mice recreate pattern of electrophysiological deficits in schizophrenia. Neuroscience 158 2 (2009) 705-712
40. Ehrlichman R.S., Maxwell C.R., Majumdar S., and Siegel S.J. Deviance-elicited changes in event-related potentials are attenuated by ketamine in mice. J Cogn Neurosci 20 8 (2008) 1403-1414
41. Ewers M., Morgan D.G., Gordon M.N., and Woodruff-Pak D.S. Associative and motor learning in 12-month-old transgenic APP+PS1 mice. Neurobiol Aging 27 8 (2006) 1118-1128
42. Felix R., and Levin E.D. Nicotinic antagonist administration into the ventral hippocampus and spatial working memory in rats. Neuroscience 81 4 (1997) 1009-1017
43. Fernandes C., Hoyle E., Dempster E., Schalkwyk L.C., and Collier D.A. Performance deficit of alpha7 nicotinic receptor knockout mice in a delayed matching-to-place task suggests a mild impairment of working/episodic-like memory. Genes Brain Behav 5 6 (2006) 433-440
44. Frangou S., Sharma T., Alarcon G., Sigmudsson T., Takei N., et al. The Maudsley Family Study, II, endogenous event-related potentials in familial schizophrenia. Schizophr Research 23 1 (1997) 45-53
45. Frazier C.J., Buhler A.V., Weiner J.L., and Dunwiddie T.V. Synaptic potentials mediated via alpha-bungarotoxin-sensitive nicotinic acetylcholine receptors in rat hippocampal interneurons. J Neurosci 18 20 (1998) 8228-8235
46. Freedman R. Electrophysiological phenotypes. Methods Mol Med 77 (2003) 215-225
47. Freedman R., Adler L.E., Bickford P., Byerley W., Coon H., Cullum C.M., et al. Schizophrenia and nicotinic receptors. Harv Rev Psychiatry 2 4 (1994) 179-192
48. Freedman R., Adler L.E., Waldo M.C., Pachtman E., and Franks R.D. Neurophysiological evidence for a defect in inhibitory pathways in schizophrenia, comparison of medicated and drug-free patients. Biol Psychiatry 18 (1983) 537-551
49. Freedman R., Coon H., Myles-Worsley M., Orr-Urtreger A., Olincy A., et al. Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc Natl Acad Sci U S A 94 2 (1997) 587-592
50. Freedman R., Olincy A., Buchanan R.W., Harris J.G., Gold J.M., et al. Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry 165 8 (2008) 1040-1047
51. Freedman R., Hall M., Adler L.E., and Leonard S. Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol Psychiatry 38 1 (1995) 22-33
52. Fujii S., and Sumikawa K. Acute and chronic nicotine exposure reverse age-related declines in the induction of long-term potentiation in the rat hippocampus. Brain Res 894 2 (2001) 347-353
53. Fujii S., and Sumikawa K. Nicotine accelerates reversal of long-term potentiation and enhances long-term depression in the rat hippocampal CA1 region. Brain Res 894 2 (2001) 340-346
54. Galindo-Charles L., Hernandez-Lopez S., Galarraga E., Tapia D., Bargas J., et al. Serotoninergic dorsal raphe neurons possess functional postsynaptic nicotinic acetylcholine receptors. Synapse 62 8 (2008) 601-615
55. Geyer M.A., Krebs-Thomson K., Braff D.L., and Swerdlow N.R. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia, a decade in review. Psychopharmacology (Berl) 156 2-3 (2001) 117-154
56. Gotti C., and Clementi F. Neuronal nicotinic receptors, from structure to pathology. Prog Neurobiol 74 6 (2004) 363-396
57. Gotti C., Riganti L., Vailati S., and Clementi F. Brain neuronal nicotinic receptors as new targets for drug discovery. Curr Pharm Des 12 4 (2006) 407-428
58. Grauer S.M., and Marquis K.L. Intracerebral administration of metabotropic glutamate receptor agonists disrupts prepulse inhibition of acoustic startle in Sprague-Dawley rats. Psychopharmacology (Berl) 141 4 (1999) 405-412
59. Gray R., Rajan A.S., Radcliffe K.A., Yakehiro M., and Dani J.A. Hippocampal synaptic transmission enhanced by low concentrations of nicotine. Nature 383 6602 (1996) 713-716
60. Guan Z.Z., Zhang X., Blennow K., and Nordberg A. Decreased protein level of nicotinic receptor alpha7 subunit in the frontal cortex from schizophrenic brain. Neuroreport 10 8 (1999) 1779-1782
61. Guntekin B., Saatçi E., and Yener G. Decrease of evoked delta, theta and alpha coherences in Alzheimer patients during a visual oddball paradigm. Brain Res 1235 (2008) 109-116
62. Hajos N., Palhalmi J., Mann E.O., Nemeth B., Paulsen O., and Freund T.F. Spike timing of distinct types of GABAergic interneuron during hippocampal gamma oscillations in vitro. J Neurosci 24 41 (2004) 9127-9137
63. Hajos M., Hoffmann W.E., Orbán G., Kiss T., and Erdi P. Modulation of septo-hippocampal Theta activity by GABAA receptors, an experimental and computational approach. Neuroscience 126 3 (2004) 599-610
64. Hajos M., Hurst R.S., Hoffmann W.E., Krause M., Wall T.M., et al. The selective α7 nicotinic acetylcholine receptor agonist PNU-282987 [N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-4-chlorobenzamide hydrochloride] enhances GABAergic synaptic activity in brain slices and restores auditory gating deficits in anesthetized rats. J Pharmacol Exp Ther 312 (2005) 1213-1222
65. Hashimoto K., Ishima T., Fujita Y., Matsuo M., Kobashi T., et al. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the novel selective α7 nicotinic receptor agonist SSR180711. Biol Psychiatry 63 1 (2008) 92-97
66. Hejl A.M., Glenthøj B., Mackeprang T., Hemmingsen R., and Waldemar G. Prepulse inhibition in patients with Alzheimer's disease. Neurobiol Aging 25 8 (2004) 1045-1050
67. Hogg R.C., Raggenbass M., and Bertrand D. Nicotinic acetylcholine receptors, from structure to brain function. Rev Physiol Biochem Pharmacol 147 (2003) 1-46
68. Hoyle E., Genn R.F., Fernandes C., and Stolerman I.P. Impaired performance of alpha7 nicotinic receptor knockout mice in the five-choice serial reaction time task. Psychopharmacology (Berl) 189 2 (2006) 211-223
69. Hu L., Boutros N.N., and Jansen B.H. Evoked potential variability. J Neurosci Methods 178 1 (2009) 228-236
70. Hunter B.E., de Fiebre C.M., Papke R.L., Kem W.R., and Meyer E.M. A novel nicotinic agonist facilitates induction of long-term potentiation in the rat hippocampus. Neurosci Lett 168 1-2 (1994) 130-134
71. Hurst R.S., Hajos M., Raggenbass M., Wall T.M., Higdon N.R., Lawson J.A., et al. A novel positive allosteric modulator of the α7 neuronal nicotinic acetylcholine receptor, in vitro and in vivo characterization. J Neurosci 25 (2005) 4396-4405
72. Jessen F., Kucharski C., Fries T., Papassotiropoulos A., Hoenig K., et al. Sensory gating deficit expressed by a disturbed suppression of the P50 event-related potential in patients with Alzheimer's disease. Am J Psychiatry 158 8 (2001) 1319-1321
73. Ji D., and Dani J.A. Inhibition and disinhibition of pyramidal neurons by activation of nicotinic receptors on hippocampal interneurons. J Neurophysiol 83 5 (2000) 2682-2690
74. Ji D., Lape R., and Dani J.A. Timing and location of nicotinic activity enhances or depresses hippocampal synaptic plasticity. Neuron 31 1 (2001) 131-141
75. Jin Y., Potkin S.G., Patterson J.V., Sandman C.A., Hetrick W.P., and Bunney Jr. W.E. Effects of P50 temporal variability on sensory gating in schizophrenia. Psychiatry Res 70 (1997) 71-81
76. Jones S., Sudweeks S., and Yakel J.L. Nicotinic receptors in the brain, correlating physiology with function. Trends Neurosci. 22 12 (1999) 555-561
77. Keller J.J., Keller A.B., Bowers B.J., and Wehner J.M. Performance of alpha7 nicotinic receptor null mutants is impaired in appetitive learning measured in a signaled nose poke task. Behav Brain Res. 162 1 (2005) 143-152
78. Kessler D., and Steinberg A. Evoked potential variation in schizophrenic subgroups. Biological Psychiatry 26 (1989) 372-380
79. Klein R.C., and Yakel J.L. Paired-pulse potentiation of α7-containing nAChRs in rat hippocampal CA1 stratum radiatum interneurones. J Physiol. 568 3 (2005) 881-889
80. Koch M. The neurobiology of startle. Prog Neurobiol 59 2 (1999) 107-128
81. Koch M., and Schnitzler H.U. The acoustic startle response in rats-circuits mediating evocation, inhibition and potentiation. Behav Brain Res 89 1-2 (1997) 35-49
82. Koike K., Hashimoto K., Takai N., Shimizu E., Komatsu N., et al. Tropisetron improves deficits in auditory P50 suppression in schizophrenia. Schizophr Research 76 (2005) 67-72
83. Koles Z.J., Lind J.C., and Flor-Henry P. A source-imaging (low-resolution electromagnetic tomography) study of the EEGs from unmedicated men with schizophrenia. Psychiatry Res 130 2 (2004) 171-190
84. Knott V., Bosman M., Mahoney C., Ilivitsky V., and Quirt K. Transdermal nicotine, single dose effects on mood, EEG, performance, and event-related potentials. Pharmacol Biochem Behav 63 2 (1999) 253-261
85. Krause M., Hoffmann W.E., and Hajós M. Auditory sensory gating in hippocampus and reticular thalamic neurons in anesthetized rats. Biol Psychiatry 53 3 (2003) 244-253
86. Lee K.H., Williams L.M., Haig A., and Gordon E. "Gamma (40 Hz) phase synchronicity" and symptom dimensions in schizophrenia. Cognit Neuropsychiatry 8 1 (2003) 57-71
87. Leiser S.C., Bowlby M.R., and Dunlop J. Electrophysiological endophenotypes in rodent models of schizophrenia and effects following nicotinic receptor activation. Program No. 156.16. 2008 Neuroscience Meeting Planner (2008), Society for Neuroscience, Washington, DC Online
88. Levin E.D., and Chen E. Nicotinic involvement in memory function in zebrafish. Neurotoxicol & Teratol 26 6 (2004) 731-735
89. Levin E.D., and Simon B.B. Nicotinic acetylcholine involvement in cognitive function in animals. Psychopharmacology 138 3-4 (1998) 217-230
90. Levin E.D., Bettegowda C., Blosser J., and Gordon J. AR-R17779, and alpha7 nicotinic agonist, improves learning and memory in rats. Behav Pharmacol 10 6-7 (1999) 675-680
91. Levin E.D., Bradley A., Addy N., and Sigurani N. Hippocampal alpha 7 and alpha 4 beta 2 nicotinic receptors and working memory. Neuroscience 109 4 (2002) 757-765
92. Levin E.D., McClernon F.J., and Rezvani A.H. Nicotinic effects on cognitive function, behavioral characterization, pharmacological specification, and anatomic localization. Psychopharmacology (Berl) 184 3-4 (2006) 523-539
93. Levin E.D., Rose J.E., and Abood L. Effects of nicotinic dimethylaminoethyl esters on working memory performance of rats in the radial-arm maze. Pharmacol Biochem Behav 51 2-3 (1995) 369-373
94. Lewis D.A., Hashimoto T., and Volk D.W. Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci 6 4 (2005) 312-324
95. Logue S.F., Grauer S.M., Scali C., Roncarati R., Marquis K.L., et al. A series of molecules acting as potent alpha7 nAChR agonists with antipsychotic properties. Program No. 94.13. 2006 Neuroscience Meeting Planner (2006), Society for Neuroscience, Atlanta, GA Online
96. Luntz-Leybman V., Bickford P.C., and Freedman R. Cholinergic gating of response to auditory stimuli in rat hippocampus. Brain Res 587 1 (1992) 130-136
97. Mansvelder H.D., Keath J.R., and McGehee D.S. Synaptic mechanisms underlie nicotine-induced excitability of brain reward areas. Neuron 33 6 (2002) 905-919
98. Markand O.N. Pearls, perils, and pitfalls in the use of the electroencephalogram. Semin Neurol 23 1 (2003) 7-46
99. Martin L.F., and Freedman R. Schizophrenia and the α7 nicotinic acetylcholine receptor. Int Rev Neurobiol 78 (2007) 225-246
100. Martin-Ruiz C.M., Haroutunian V.H., Long P., Young A.H., Davis K.L., et al. Dementia rating and nicotinic receptor expression in the prefrontal cortex in schizophrenia. Biol Psychiatry 54 11 (2003) 1222-1233
101. Marubio L.M., and Paylor R. Impaired passive avoidance learning in mice lacking central neuronal nicotinic acetylcholine receptors. Neuroscience 129 3 (2004) 575-582
102. McBride T., Moberg P.J., Arnold S.E., Mozley L.H., Mahr R.N., et al. Neuropsychological functioning in elderly patients with schizophrenia and Alzheimer's disease. Schizophr Research 55 3 (2002) 217-227
103. McGehee D.S. Nicotinic receptors and hippocampal synaptic plasticity. it's all in the timing. Trends Neurosci 25 4 (2002) 171-172
104. Meck W.H., Smith R.A., and Williams C.L. Pre- and postnatal choline supplementation produces long-term facilitation of spatial memory. Dev Psychobiol 21 4 (1988) 339-353
105. Metzger K.L., Maxwell C.R., Liang Y., and Siegel S.J. Effects of nicotine vary across two auditory evoked potentials in the mouse. Biol Psychiatry 61 (2007) 23-30
106. Meyer E.M., Tay E.T., Papke R.L., Meyers C., Huang G.L., and de Fiebre C.M. 3-[2,4-Dimethoxybenzylidene]anabaseine (DMXB) selectively activates rat alpha7 receptors and improves memory-related behaviors in a mecamylamine-sensitive manner. Brain Res 768 1-2 (1997) 49-56
107. Michie P.T., Fox A.M., Ward P.B., Catts S.V., and McConaghy N. Event-related potential indices of selective attention and cortical lateralization in schizophrenia. Psychophysiology 27 2 (1990) 209-227
108. Mientus S., Gallinat J., Wuebben Y., Pascual-Marqui R.D., Mulert C., et al. Cortical hypoactivation during resting EEG in schizophrenics but not in depressives and schizotypal subjects as revealed by low resolution electromagnetic tomography (LORETA). Psychiatry Res 116 1-2 (2002) 95-111
109. Moretti D.V., Babiloni C., Binetti G., Cassetta E., Dal Forno G., et al. Individual analysis of EEG frequency and band power in mild Alzheimer's disease. Clin Neurophysiol 115 2 (2004) 299-308
110. Moxon K.A., Gerhardt G.A., Bickford P.C., Austin K., Rose G.M., et al. Multiple single units and population responses during inhibitory gating of hippocampal auditory response in freely-moving rats. Brain Res 825 (1999) 75-85
111. Moxon K.A., Gerhardt G.A., Gulinello M., and Adler L.E. Inhibitory control of sensory gating in a computer model of the CA3 region of the hippocampus. Biol Cybern 88 (2003) 247-264
112. Moxon K.A., Gerhardt G.A., and Adler L.E. Dopaminergic modulation of the P50 auditory-evoked potential in a computer model of the CA3 region of the hippocampus, its relationship to sensory gating in schizophrenia. Biol Cybern 88 (2003) 265-275
113. Ng H.J., Whittemore E.R., Tran M.B., Hogenkamp D.J., Broide R.S., et al. Nootropic α7 nicotinic receptor allosteric modulator derived from GABAA receptor modulators. Proc Natl Acad Sci U S A 104 (2007) 8059-8064
114. Nott A., and Levin E.D. Dorsal hippocampal alpha7 and alpha4beta2 nicotinic receptors and memory. Brain Res 1081 1 (2006) 72-78
115. O'Donnell B.F., Faux S.F., McCarley R.W., Kimble M.O., Salisbury D.F., et al. Increased rate of P300 latency prolongation with age in schizophrenia. Arch Gen Psychiatry 52 (1995) 544-549
116. O'Donnell B.F., Shenton M.E., McCarley R.W., Faux S.F., Smith R.S., et al. The auditory N2 component in schizophrenia, relationship to MRI temporal lobe gray matter and to other ERP abnormalities. Biological Psychiatry 34 (1993) 26-40
117. O'Neill H.C., Rieger K., Kem W.R., and Stevens K.E. DMXB, an α7 nicotinic agonist, normalizes auditory gating in isolation-reared rats. Psychopharmacology (Berl) 169 (2003) 332-339
118. Olichney J.M., and Hillert D.G. Clinical applications of cognitive event-related potentials in Alzheimer's disease. Phys Med Rehabil Clin N Am 15 1 (2004) 205-233
119. Olincy A., Harris J.G., Johnson L.L., Pender V., Kongs S., Allensworth D., et al. Proof-of-concept trial of an α7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry 63 (2006) 630-638
120. Olivier B., Leahy C., Mullen T., Paylor R., Groppi V.E., et al. The DBA/2J strain and prepulse inhibition of startle, a model system to test antipsychotics?. Psychopharmacology (Berl) 156 2-3 (2001) 284-290
121. Oranje B., Geyer M.A., Bocker K.B., Leon Kenemans J., and Verbaten M.N. Prepulse inhibition and P50 suppression, commonalities and dissociations. Psychiatry Res 143 2-3 (2006) 147-158
122. Orr-Urtreger A., Göldner F.M., Saeki M., Lorenzo I., Goldberg L., et al. Mice deficient in the alpha7 neuronal nicotinic acetylcholine receptor lack alpha-bungarotoxin binding sites and hippocampal fast nicotinic currents. J Neurosci. 17 23 (1997) 9165-9171
123. Papke R.L., Kem W.R., Soti F., Lopez-Hernandez G.Y., and Horenstein N.A. Activation and desensitization of nicotinic {alpha}7-type acetylcholine receptors by benzylidene anabaseines and nicotine. J Pharmacol Exp Ther (2009) 10.1124/jpet.108.150151
124. Patterson J.V., Hetrick W.P., Boutros N.N., Jin Y., Sandman C., et al. P50 sensory gating ratios in schizophrenics and controls, a review and data analysis. Psychiatry Res 158 2 (2008) 226-247
125. Paylor R., Nguyen M., Crawley J.N., Patrick J., Beaudet A., and Orr-Urtreger A. Alpha7 nicotinic receptor subunits are not necessary for hippocampal-dependent learning or sensorimotor gating, a behavioral characterization of Acra7-deficient mice. Learn Mem 5 4-5 (1998) 302-316
126. Perl O., Ilani T., Strous R.D., Lapidus R., and Fuchs S. The alpha7 nicotinic acetylcholine receptor in schizophrenia, decreased mRNA levels in peripheral blood lymphocytes. FASEB J 17 13 (2003) 1948-1950
127. Phillips J.M., Ehrlichman R.S., and Siegel S.J. Mecamylamine blocks nicotine-induced enhancement of the P20 auditory event-related potential and evoked gamma. Neuroscience 144 (2007) 1314-1323
128. Pichat P., Bergis O.E., Terranova J.P., Urani A., Duarte C., et al. SSR180711, a novel selective alpha7 nicotinic receptor partial agonist, (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia. Neuropsychopharmacology 32 1 (2007) 17-34
129. Picton T.W. The P300 wave of the human event-related potential. J Clin Neurophysiol 9 4 (1992) 456-479
130. Potter D., Summerfelt A., Gold J., and Buchanan R.W. Review of clinical correlates of P50 sensory gating abnormalities in patients with schizophrenia. Schizophr Bull 32 4 (2006) 692-700
131. Radek R.J., Miner H.M., Bratcher N.A., Decker M.W., Gopalakrishnan M., and Bitner R.S. Alpha4beta2 nicotinic receptor stimulation contributes to the effects of nicotine in the DBA/2 mouse model of sensory gating. Psychopharmacology (Berl) 187 (2006) 47-55
132. Riley B.P., Makoff A., Mogudi-Carter M., Jenkins T., Williamson R., et al. Haplotype transmission disequilibrium and evidence for linkage of the CHRNA7 gene region to schizophrenia in Southern African Bantu families. Am J Med Genet 96 2 (2000) 196-201
133. Roncarati R., Bothmann H., Diadato E., Jow B., Lock T., et al. Discovery of a series of molecules acting as potent alpha7 nAChR agonists. Program No. 524.7. 2006 Neuroscience Meeting Planner (2006), Atlanta, GA, Society for Neuroscience Online
134. Roncarati R., Scali C., Comery T.A., Grauer S.M., Aschmies S., et al. Procognitive and neuroprotective activity of a novel {alpha}7 nicotinic acetylcholine receptor agonist for treatment of neurodegenerative and cognitive disorders. J Pharmacol Exp Ther (2009) 10.1124/jpet.108.150094
135. Rosburg T., Trautner P., Fell J., Moxon K.A., Elger C.E., and Boutros N.N. Sensory gating in intracranial recordings-the role of phase locking. Neuroimage 44 3 (2009) 1041-1049
136. Roth W.T., Horvath T.B., Pfefferbaum A., and Kopell B.S. Event-related potentials in schizophrenics. Electroencephalogr Clin Neurophysiol 48 (1980) 127-139
137. Rudnick N.D., Koehler C., Picciotto M.R., and Siegel S.J. Role of beta2-containing nicotinic acetylcholine receptors in auditory event-related potentials. Psychopharmacology (Berl). 202 4 (2009) 745-751
138. Rueter L.E., Anderson D.J., Briggs C.A., Donnelly-Roberts D.L., Gintant G.A., et al. ABT-089, pharmacological properties of a neuronal nicotinic acetylcholine receptor agonist for the potential treatment of cognitive disorders. CNS Drug Rev 10 2 (2004) 167-182
139. Sambeth A., Riedel W.J., Smits L.T., and Blokland A. Cholinergic drugs affect novel object recognition in rats, relation with hippocampal EEG?. Eur J Pharmacol 572 2-3 (2007) 151-159
140. Scaglione A., and Moxon K.A. Behaviorally modulated filter model for the thalamic reticular nucleus. Conf Proc IEEE Eng Med Biol Soc 1 (2006) 595-598
141. Schellenberg R., Todorova A., Dimpfel W., and Schober F. Pathophysiology and psychopharmacology of dementia-a new study design. I. Diagnosis comprising subjective and objective criteria. Neuropsychobiology 32 2 (1995) 81-97
142. Schreiber R., Dalmus M., and De Vry J. Effects of alpha 4/beta 2- and alpha 7-nicotine acetylcholine receptor agonists on prepulse inhibition of the acoustic startle response in rats and mice. Psychopharmacology (Berl) 159 3 (2002) 248-257
143. Siegel S.J., Connolly P., Liang Y., Lenox R.H., Gur R.E., et al. Effects of strain, novelty, and NMDA blockade on auditory-evoked potentials in mice. Neuropsychopharmacology 28 4 (2003) 675-682
144. Siegel C., Waldo M., Mizner G., Adler L.E., and Freedman R. Deficits in sensory gating in schizophrenic patients and their relatives. Arch Gen Psychiatry 41 (1984) 607-612
145. Simosky J.K., Freedman R., and Stevens K.E. Olanzapine improves deficient sensory inhibition in DBA/2 mice. Brain Res 1233 (2008) 129-136
146. Simosky J.K., Stevens K.E., Adler L.E., and Freedman R. Clozapine improves deficient inhibitory auditory processing in DBA/2 mice, via a nicotinic cholinergic mechanism. Psychopharmacol 165 (2003) 386-396
147. Simosky J.K., Stevens K.E., Kem W.R., and Freedman R. Intragastric DMXB-A, an α7 nicotinic agonist, improves deficient sensory inhibition in DBA/2 mice. Biol Psychiatry 50 (2001) 493-500
148. Siok C.J., Rogers J.A., Kocsis B., and Hajós M. Activation of alpha7 acetylcholine receptors augments stimulation-induced hippocampal theta oscillation. Eur J Neurosci 23 2 (2006) 570-574
149. Sokolova E., Matteoni C., and Nistri A. Desensitization of neuronal nicotinic receptors of human neuroblastoma SH-SY5Y cells during short or long exposure to nicotine. Br J Pharmacol 146 (2005) 1087-1095
150. Spinelli S., Ballard T., Feldon J., Higgins G.A., and Pryce C.R. Enhancing effects of nicotine and impairing effects of scopolamine on distinct aspects of performance in computerized attention and working memory tasks in marmoset monkeys. Neuropharmacology 51 2 (2006) 238-250
151. Stevens K.E., and Wear K.D. Normalizing effects of nicotine and a novel nicotinic agonist on hippocampal auditory gating in two animal models. Pharmacol Biochem Behav 57 (1997) 869-874
152. Stevens K.E., Adams C.E., Mellott T.J., Robbins E., and Kisley M.A. Perinatal choline deficiency produces abnormal sensory inhibition in Sprague-Dawley rats. Brain Res 1237 (2008) 84-90
153. Stevens K.E., Adams C.E., Yonchek J., Hickel C., Danielson J., and Kisley M.A. Permanent improvement in deficient sensory inhibition in DBA/2 mice with increased perinatal choline. Psychopharmacology (Berl) 198 3 (2008) 413-420
154. Stevens K.E., Freedman R., Collins A.C., Hall M., Leonard S., et al. Genetic correlation of inhibitory gating of hippocampal auditory evoked response and alpha-bungarotoxin-binding nicotinic cholinergic receptors in inbred mouse strains. Neuropsychopharmacology 15 2 (1996) 152-162
155. Stevens K.E., Kem W.R., and Freedman R. Selective alpha 7 nicotinic receptor stimulation normalizes chronic cocaine-induced loss of hippocampal sensory inhibition in C3H mice. Biol Psychiatry 46 (1999) 1443-1450
156. Stevens K.E., Kem W.R., Mahnir V.M., and Freedman R. Selective α7-nicotinic agonists normalize inhibition of auditory response in DBA mice. Psychopharmacology (Berl) 136 (1998) 320-327
157. Stolerman I.P., Chamberlain S., Bizarro L., Fernandes C., and Schalkwyk L. The role of nicotinic receptor alpha 7 subunits in nicotine discrimination. Neuropharmacology 46 3 (2004) 363-371
158. Suemaru K., Yasuda K., Umeda K., Araki H., Shibata K., et al. Nicotine blocks apomorphine-induced disruption of prepulse inhibition of the acoustic startle in rats, possible involvement of central nicotinic alpha7 receptors. Br J Pharmacol 142 5 (2004) 843-850
159. Swerdlow N.R., and Geyer M.A. Using an animal model of deficient sensorimotor gating to study the pathophysiology and new treatments of schizophrenia. Schizophr Bull 24 2 (1998) 285-301
160. Swerdlow N.R., Caine S.B., and Geyer M.A. Regionally selective effects of intracerebral dopamine infusion on sensorimotor gating of the startle reflex in rats. Psychopharmacology (Berl) 108 1-2 (1992) 189-195
161. Swerdlow N.R., Varty G.B., and Geyer M.A. Discrepant findings of clozapine effects on prepulse inhibition of startle, is it the route or the rat?. Neuropsychopharmacology 18 1 (1998) 50-56
162. Swerdlow N.R., Taaid N., Oostwegel J.L., Randolph E., and Geyer M.A. Towards a cross-species pharmacology of sensorimotor gating, effects of amantadine, bromocriptine, pergolide and ropinirole on prepulse inhibition of acoustic startle in rats. Behav Pharmacol 9 5-6 (1998) 389-396
163. Swerdlow N.R., van Bergeijk D.P., Bergsma F., Weber E., and Talledo J. The effects of memantine on prepulse inhibition. Neuropsychopharmacology (2009) 10.1038/npp.2009.7
164. Terry Jr. A.V., and Gearhart D.A. Time dependent decreases in central alpha7 nicotinic acetylcholine receptors associated with haloperidol and risperidone treatment in rats. Eur J Pharmacol 571 1 (2007) 29-32
165. Thomas C., Vom Berg I., Rupp A., Seidl U., Schröder J., et al. P50 gating deficit in Alzheimer dementia correlates to frontal neuropsychological function. Neurobiol Aging (2008) 10.1016/j.neurobiolaging.2008.05.002
166. Thompson P.M., Hayashi K.M., Sowell E.R., Gogtay N., Giedd J.N., et al. Mapping cortical change in Alzheimer's disease, brain development, and schizophrenia. Neuroimage 23 Suppl 1 (2004) S2-18
167. Tietje K.R., Anderson D.J., Bitner R.S., Blomme E.A., Brackemeyer P.J., et al. Preclinical characterization of A-582941, a novel alpha7 neuronal nicotinic receptor agonist with broad spectrum cognition-enhancing properties. CNS Neurosci Ther 14 1 (2008) 65-82
168. Timmermann D.B., Grønlien J.H., Kohlhaas K.L., Nielsen E.Ø., Dam E., et al. An allosteric modulator of the alpha7 nicotinic acetylcholine receptor possessing cognition-enhancing properties in vivo. J Pharmacol Exp Ther 323 1 (2007) 294-307
169. Turetsky B.I., Bilker W.B., Siegel S.J., Kohler C.G., and Gur R.E. Profile of auditory information-processing deficits in schizophrenia. Psychiatry Res 165 1-2 (2009) 27-37
170. Ueki A., Goto K., Sato N., Iso H., and Morita Y. Prepulse inhibition of acoustic startle response in mild cognitive impairment and mild dementia of Alzheimer type. Psychiatry Clin Neurosci 60 1 (2006) 55-62
171. van der Stelt O., Belger A., and Lieberman J.A. Macroscopic fast neuronal oscillations and synchrony in schizophrenia. Proc Natl Acad Sci U S A 101 51 (2004) 17567-17568
172. Van Kampen M., Selbach K., Schneider R., Schiegel E., Boess F., and Schreiber R. AR-R 17779 improves social recognition in rats by activation of nicotinic alpha7 receptors. Psychopharmacology (Berl) 172 4 (2004) 375-383
173. Wildeboer K.M., and Stevens K.E. Stimulation of the alpha4beta2 nicotinic receptor by 5-I A-85380 improves auditory gating in DBA/2 mice. Brain Res 1224 (2008) 29-36
174. Woodruff-Pak D.S. Mecamylamine reversal by nicotine and by a partial alpha7 nicotinic acetylcholine receptor agonist (GTS-21) in rabbits tested with delay eyeblink classical conditioning. Behav Brain Res 143 2 (2003) 159-167
175. Woodruff-Pak D.S., and Santos I.S. Nicotinic modulation in an animal model of a form of associative learning impaired in Alzheimer's disease. Behav Brain Res 113 1-2 (2000) 11-19
176. Yaguchi T., Nagata T., and Nishizaki T. Dilinoleoylphosphatidylcholine ameliorates scopolamine-induced impairment of spatial learning and memory by targeting alpha7 nicotinic ACh receptors. Life Sci 84 9-10 (2009) 263-266
177. Yener G., Güntekin B., and Başar E. Event-related delta oscillatory responses of Alzheimer patients. Eur J Neurol 15 6 (2008) 540-547
178. Young J.W., Crawford N., Kelly J.S., Kerr L.E., Marston H.M., et al. Impaired attention is central to the cognitive deficits observed in alpha 7 deficient mice. Eur Neuropsychopharmacol 17 2 (2007) 145-155